Brilliant Medicine innovation Co., Ltd.
Update：2026/09/15
Industries
Main Industry
Health Care
Main Product/Service
1. Pet Malignant Tumor Novel Drug Development Platform: Dedicated to the development of therapeutic drugs targeting life-threatening malignant tumors in pets, utilizing the platform to develop cross-species, broad-spectrum treatments for malignant tumors.
2. Enhanced Pet Health Supplements: Developed to target specific pet physiological functions and physical health. Applying drug development principles, these supplements utilize small-molecule ingredients to reinforce pet health, such as for joints, vision, coat, and more.
(The content above was translated by AI.)
2. Enhanced Pet Health Supplements: Developed to target specific pet physiological functions and physical health. Applying drug development principles, these supplements utilize small-molecule ingredients to reinforce pet health, such as for joints, vision, coat, and more.
(The content above was translated by AI.)
Founded Year
2022
Unified Business No.
90315543
Status
Active
Number of Employees
0
Total Paid-in
Capital
3,000,000 (NT$)
Location of Company
Taiwan
, Taichung City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Brilliant Medicine innovation Co., Ltd. focuses on developing novel drugs for the treatment of broad-spectrum and refractory pet malignant tumors, as well as pet health-enhancing foods. Brilliant Medicine innovation Co., Ltd. collaborates with multiple universities and medical research departments, integrating cutting-edge scientific technologies across multiple fields to target continuously activated oncoproteins within the metabolic pathways of malignant tumors for drug therapy.
(The content above was translated by AI.)
(The content above was translated by AI.)
